Axel Hauschild, MD, on Clinical Implications of Using Neoadjuvant Daromun in Locally Advanced Melanoma

Posted: Friday, June 28, 2024

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses practical clinical questions about phase III findings from the PIVOTAL study of neoadjuvant intralesional daromun vs immediate surgery in patients with fully resectable melanoma with regional skin and/or nodal metastases.